Discovery of Indenopyrazoles as a New Class of Hypoxia Inducible Factor (HIF)-1 Inhibitors
摘要:
The indenopyrazole framework was investigated as a new class of HIP-la inhibitors. Indenopyrazole 21 was found to most strongly inhibit the hypoxia-induced HIF-1 alpha transcriptional activity (IC50 = 0.014 mu M) among all of the known compounds having relatively simple structures, unlike manassantins. Indenopyrazole 21 suppressed HIP-la transcriptional activity without affecting both HIF-1 alpha protein accumulation and HIF-1 alpha HIF-1 beta heterodimerization in nuclei under the hypoxic conditions, suggesting that 21 probably affected the transcriptional pathway induced by the HIF-1 alpha/HIF-1 beta heterodimer.
N-substituted tricyclic 1-aminopyrazoles as inhibitors for the treatment of cell proliferative disorders
申请人:Ho Yung Chih
公开号:US20070142305A1
公开(公告)日:2007-06-21
The invention is directed to N-substituted tricyclic 3-AMINOPYRAZOLE derivatives, which are useful as inhibitors of platelet-derived growth factor receptor (PDGF-R) kinase, and methods for the preparation of said derivatives. The present invention is further directed to pharmaceutical compositions comprising the compounds of the present invention and to methods for treating conditions such as tumors and other cell. proliferative disorders.
(6,7-Dimethoxy-2,4-dihydroindeno[1,2-<i>c</i>]pyrazol-3-yl)phenylamines: Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors with Broad Antiproliferative Activity against Tumor Cells
作者:Chih Y. Ho、Donald W. Ludovici、Umar S. M. Maharoof、Jay Mei、Jan L. Sechler、Robert W. Tuman、Eric D. Strobel、Laura Andraka、Hwa-Kwo Yen、Gregory Leo、Jian Li、Harold Almond、Hong Lu、Ann DeVine、Rose M. Tominovich、Judith Baker、Stuart Emanuel、Robert H. Gruninger、Steven A. Middleton、Dana L. Johnson、Robert A. Galemmo
DOI:10.1021/jm050680m
日期:2005.12.1
A series of (6,7-dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines has been optimized to preserve both potent kinase inhibition activity against the angiogenesis target, the receptor tyrosine kinase of Platelet-Derived Growth Factor-BB (PDGF-BB), and to improve the broad tumor cell antiproliferative activity of these compounds. This series culminates in the discovery of 17 (JNJ-10198409), a compound with anti-PDGFR-beta kinase activity (IC50 = 0.0042 mu M) and potent antiproliferative activity in six of eight human tumor cell lines (IC50 < 0.033 mu m).
N-SUBSTITUTED TRICYCLIC 3-AMINOPYRAZOLES AS PDGF RECEPTOR INHIBITORS
申请人:Janssen Pharmaceutica NV
公开号:EP1506175B1
公开(公告)日:2009-04-01
RADIOLABELED MICROTUBULE IMAGING COMPOUNDS AND USES THEREOF
申请人:The Trustees of Columbia University in the City of New York
公开号:US20200290976A1
公开(公告)日:2020-09-17
The present disclosure relates to radiolabeled compounds and methods of uses for diagnosis, monitoring, and treatment of various degenerative neurological disorders, neuropsychiatric disorders, brain injuries, vascular diseases, and cancers. Radiolabled compounds for imaging of microtubules or microtubules and other targets using positron-emission tomography (PET) are specifically disclosed.